Clinical Trials on Coenzyme Q10 Pharmacokinetics in Canada
Total 33 results
-
Factors Group of Nutritional Companies Inc.IsuraCompleted
-
Journey Medical CorporationDr. Reddy's Laboratories LimitedCompleted
-
Université de MontréalUnknown
-
Centre hospitalier de l'Université de Montréal...Completed
-
University of AlbertaCompleted
-
Factors Group of Nutritional Companies Inc.CompletedPharmacokineticsCanada
-
Factors Group of Nutritional Companies Inc.CompletedPharmacokineticsCanada
-
Factors Group of Nutritional Companies Inc.Completed
-
Centre hospitalier de l'Université de Montréal...CompletedAnesthesia, Local | PharmacokineticsCanada
-
Endo PharmaceuticalsSFBC AnapharmCompletedPharmacokinetics | Bioavailability | AbsorptionCanada
-
Il-Yang Pharm. Co., Ltd.CompletedHealthy | Pharmacokinetics | Pharmacodynamics | IlaprazoleCanada
-
Inversago Pharma Inc.Completed
-
Akebia TherapeuticsCompletedPharmacokinetics | Drug Interaction PotentiationCanada
-
Children's Hospital of Eastern OntarioRecruitingPharmacokinetics of Celecoxib in ChildrenCanada
-
University of SaskatchewanSaskatchewan Health Research Foundation; Lung Association of SaskatchewanCompletedPharmacokinetics | Lung Transplant | Kidney TransplantCanada
-
KGK Science Inc.ChromaDex, Inc.CompletedPharmacokineticsCanada
-
Samuel FortinCompleted
-
Vanda PharmaceuticalsCompletedPharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With EthanolCanada
-
Ottawa Hospital Research InstituteCompletedCritical Illness | Pharmacokinetics | Kidney InjuryCanada
-
PfizerCompletedPharmacokinetics | Safety | ECGCanada, Spain, United States, Hungary, Poland, United Kingdom
-
Unity Health TorontoCompletedReal Function Post Conversion From Prograf to Advagraf | Examin Ethnicity and Pharmacogenetics of the Cohort Requiring Dose Adjustment Post-conversionCanada
-
Pacific Parkinson's Research CentreCompleted
-
ShirePPDCompletedAngiotensin Converting Enzyme Inhibitor Induced AngioedemaUnited States, Canada, United Kingdom, Israel
-
National Cancer Institute (NCI)TerminatedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Secondary Acute Myeloid Leukemia and other conditionsCanada
-
CytokineticsCompletedChronic Heart Failure | Pharmacokinetics | Left Ventricular Systolic Dysfunction | Left Ventricular Ejection Fraction | Modified Release Oral Formulation | History of Chronic Heart Failure | EchocardiogramUnited States, Canada, Italy, Netherlands, United Kingdom, Belgium, Czechia, Australia, Hungary, Poland, Bulgaria, Lithuania, Germany
-
OctapharmaCompletedPrimary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIGCanada, Austria, France, Spain, United Kingdom
-
ProQR TherapeuticsRecruitingEye Diseases | Neurologic Manifestations | Retinal Degeneration | Retinal Dystrophies | Sensation Disorders | Vision Disorders | Blindness | Leber Congenital Amaurosis | Leber Congenital Amaurosis 10 | Retinal Disease | Eye Disorders CongenitalBelgium, Brazil, Canada, Germany, Italy, Netherlands, United Kingdom
-
AstraZenecaActive, not recruitingCervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 PositiveUnited States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
-
ProQR TherapeuticsActive, not recruitingEye Diseases | Neurologic Manifestations | Eye Diseases, Hereditary | Sensation Disorders | Vision Disorders | Blindness | Leber Congenital Amaurosis | Leber Congenital Amaurosis 10 | Retinal Disease | Eye Disorders CongenitalUnited States, Belgium, Brazil, Canada, France, Germany, Italy, Netherlands, United Kingdom
-
National Cancer Institute (NCI)CompletedRecurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditionsCanada
-
National Cancer Institute (NCI)CompletedPrimary Myelofibrosis | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Disease | Recurrent Adult Acute Lymphoblastic Leukemia | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic... and other conditionsUnited States, Canada, New Zealand
-
Eli Lilly and CompanyActive, not recruitingUrogenital Neoplasms | Prostatic Neoplasms | Neoplasm Metastasis | Enzyme Inhibitors | Antineoplastic Agents | Hormones | Physiological Effects of Drugs | Antineoplastic Agents, Hormonal | Androgens | Hormones, Hormone Substitutes, and Hormone Antagonists | Abiraterone Acetate | Steroid Synthesis Inhibitors | Cytochrome... and other conditionsChina, Canada, France, United States, Australia, Czechia, Hungary, Spain, Germany, Japan, Taiwan, Netherlands, Mexico, Belgium, Korea, Republic of, Turkey, Argentina, Romania, United Kingdom, Italy, Israel, Brazil, Poland, Greece
-
National Cancer Institute (NCI)CompletedRecurrent Adult Acute Myeloid Leukemia | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation (M1) | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities and other conditionsUnited States, Canada, Australia